Gynius · Checked.be

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of Gynius is 0.1% (very low). The 2025 annual accounts show equity of €39k and a net result of €116k. Equity is growing by ~34.5% per year across the filed fiscal years. Its solvency ranks better than 22% of 2217 sector peers (fiscal year 2025). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 5 annual accounts.

Signals

2 signals · with evidence

Weak solvency vs sector

Solvency (equity / total assets) is in the sector's weakest quartile: better than 22% of 2217 sector peers (2025).

View the sector comparison

Consistently profitable

Positive net result in the two most recent financial years (2024 and 2025).

View the result trend

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Filing behaviour

From the deposit records, complete market-wide

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 01-04-2026, 121 days ahead of the deadline. This speaks to administrative punctuality and says nothing about the financial position.

The next deadline is still running

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.

How we compute the deadline

The year end is derived from 5 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2025, that is 31-07-2026.

Deadline per financial year

Year closed	Due by	Filed	Variance	Reference
31-12-2025	31-07-2026	01-04-2026	121 d early	2026-00072238
31-12-2024	31-07-2025	06-07-2025	25 d early	2025-00241113
31-12-2023	31-07-2024	18-07-2024	13 d early	2024-00256952
31-12-2022	31-07-2023	07-08-2023	7 d late	2023-00315957
31-12-2021	31-07-2022	22-08-2022	22 d late	2022-20318512

Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.

Trust signals

2 signals

More than 3 years active

Founded in 2020, past the statistically most fragile first 3 years.

No legal incidents

No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone

0.1% Very low

0%0,5%1,5%4%10%≥25%

Lower-failure-rate sector −Young company +Annual accounts: healthy financial profile −

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

TurnoverNot published (abbreviated filing)

EBIT marginNot published (abbreviated filing)

Net result€116k-12.6%

Working capital€34k-82.8%

CSV export

Annual accounts & ratios

Source: NBB · 2025

Annual accounts filed on 01-04-2026 with the NBB · fiscal year 2025 · micro

Operating resultNet result

Trajectory (indicative)

Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.

growing Equity: growth of ~34.5%/year over 5 fiscal years, indicative, assuming unchanged policy.

Solid line = filed figures · dashed = extended trend · area = indicative range.

How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison

Fiscal year 2025 · NACE 86, Human health · compared within the same schema type (micro schema)

Metric	This company	Sector median	Position in the sector
Solvency	9.7%	58.2%	better than 22% of 2217 sector peers
Net result	€116k	€60k	better than 76% of 2215 sector peers
Equity	€39k	€74k	better than 37% of 2217 sector peers
Gross operating margin	€171k	€95k	better than 73% of 2217 sector peers
Total assets	€400k	€186k	better than 79% of 2217 sector peers

Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.

Sector position over time

Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).

Solvency P22

Weakening position over 2021-2025 · n=1848-6582

Net result P76

Improving position over 2021-2025 · n=1848-6576

Equity P37

Stable position over 2021-2025 · n=1848-6582

Gross operating margin P73

Improving position over 2021-2025 · n=1849-6584

Describes the position versus peers, not a forecast.

EBITDA

€171k

-9.5% 21-25

Net profit

€116k

-12.6% 21-25

Cash flow

€129k

-9.3% 21-25

Total assets

€400k

+9.0% 21-25

Equity

€39k

-82.1% 21-25

Working capital

€34k

-82.8% 21-25

Income taxes

€35k

-15.6% 21-25

Dividends

€293k

+154.9% 21-25

Debt

€361k

+138.6% 21-25

Debt ≤ 1y

€323k

+196.0% 21-25

Debt > 1y

€32k

-25.1% 21-25

Current ratio

1.10

-60.4% 21-25

Quick ratio

1.10

-60.4% 21-25

Solvency

9.7%

-83.6% 21-25

Debt / equity

9.36

+1231.5% 21-25

ROE

301.8%

+387.8% 21-25

ROA

29.1%

-19.8% 21-25

Interest coverage

19.96

-44.8% 21-25

Figures by fiscal year

Highlight YoY changes (±10%)

Fiscal year	2025
Deposit	micro
Revenue	-
EBITDA	€171k
Net profit	€116k
Cash flow	€129k
Staff costs	-
Income taxes	€35k
Dividends	€293k
Total assets	€400k
Equity	€39k
Debt	€361k
of which ≤ 1y	€323k
of which > 1y	€32k
Working capital	€34k
Employees (FTE)	-

Ratios (computed)

	2025
Current ratio	1.10
Quick ratio	1.10
Working capital ratio	8.4%
Solvency	9.7%
Debt / equity	9.36
Long-term debt ratio	0.82
Interest coverage	19.96
Gross margin	-
Net margin	-
ROA	29.1%
ROE	301.8%
EBITDA margin	-
Days sales outstanding	-
Days payable outstanding	-
Inventory turnover	-
Days inventory (DSI)	-

Balance-sheet composition 2025

Assets

Fixed assets €43k · 10.7% Current assets €357k · 89.3%

Equity & liabilities

Equity €39k · 9.7% Debt €361k · 90.3%

Full annual accounts

Filed balance sheet and income statement, exactly as deposited with the NBB.

Line item	Code	2025
Balance sheet, Assets
TOTAL ASSETS	20/58	€400k
Fixed assets	21/28	€43k
Tangible fixed assets	22/27	€43k
Financial fixed assets	28	€200
Current assets	29/58	€357k
Amounts receivable within one year	40/41	€913
Cash & bank	54/58	€320k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€400k
Equity	10/15	€39k
Contributions / capital	10/11	€7k
Reserves	13	€32k
Amounts payable	17/49	€361k
Amounts payable after one year	17	€32k
Amounts payable within one year	42/48	€323k
Trade debts payable within one year	44	€5k
Income statement
Gross operating margin	9900	€171k
Operating result	9901	€158k
Financial income	75	€2k
Financial charges	65	€9k
Result before taxes	9903	€151k
Income taxes	67/77	€35k
Net result for the period	9904	€116k
Result to be appropriated	9905	€116k

This table shows the latest fiscal year. 4 prior years, with figures and ratios, belong to a paid plan. See plans →

Ratios computed by Checked.

Health barometer

FY 2025 · computed

65 / 100 Healthy

050100

Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.

See plans →

Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.

Structure & network

Locations & real estate

Registered office

on the map · from the address register

exact location from the address register On OpenStreetMap

4 companies at this address See who is registered here

Establishment units

1 location

Siegersveldstraat 32, 3500 Hasselt

Activiteiten van medisch specialisten

since 20202.309.247.128

Physical sites registered in the Crossroads Bank for Enterprises (CBE).

Parcels1

Ground area3,742 m²

Buildings1

Building footprint386 m²

Volume (LiDAR)1,805 m³

Tallest building14.3 m · ±1 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 1 (100%)